Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Ilmu Farmasi dan Farmasi Klinik (Journal of Pharmaceutical Science and Clinical Pharmacy) Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya
Ita Octafia
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment Ita Octafia; Dwi Octamy Sari; Novi Wulandari; Sandra Annisa; Linda Wahyuni Wongkar; Ferdias Kurnia Bahari; Faiz Farikhah; Moh Firmansah; Erfin Midhiawati; Fauna Herawati
Qanun Medika - Jurnal Kedokteran FK UMSurabaya Vol 5, No 1 (2021)
Publisher : Universitas Muhammadiyah Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30651/jqm.v5i1.5043

Abstract

Abstract Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway inflammation with resulting progressive airflow limitation that has a high incidence, morbidity, and mortality. Roflumilast is an oral phosphodiesterase-4 inhibitor as a therapy to decrease the risk of COPD exacerbations in patients with moderate-severe COPD with a history of chronic bronchitis. Roflumilast can be given orally once daily as a single or combination drug. It can be used as COPD moderate-severe but also more beneficial as COPD mild treatment. The efficacy of Roflumilast can prevent exacerbations of repetition and can fixed lung function both in terms of FEV1 and vital capacity to force. The incidence of side effects, which are diarrhea and digestive disorders. The cost-effectiveness showed that Quality of life patient with Roflumilast is better than the group without additional. This paper aimed to review systematically Roflumilast as COPD treatment for the clinical application.Keywords                   : COPD, Roflumilast, phosphodiesterase-4 inhibitorCorrespondence          : fauna@staff.ubaya.ac.id
Studi Efektivitas Ketorolak Versus Metamizol Untuk Nyeri Paska Operasi Transurethral Resection Of The Prostate (TURP) Ita Octafia; Riza Mazidu Sholihin; Yosi Irawati Wibowo; Adji Prayitno Setiadi
Jurnal Ilmu Farmasi dan Farmasi Klinik No 1 (2024): JIFFK Special Edition Suppl. 2
Publisher : Universitas Wahid Hasyim Semarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31942/jiffk.v2i1.9197

Abstract

Limited evidence was available on the use of analgesic post-transurethral resection among patients with Benign Prostate Hyperplasia (BPH). This research was conducted at dr. Harjono Ponorogo Regional Public Hospital in September – November 2021. A total of 90 patients with BPH was randomly assigned to receive Ketorolac injection 30 mg (n=45) and Metamizole 1000 mg injection (n=45) post-TURP. Numeric Rating Scale (NRS) was used to measure the level of pain before surgery (T0); and 30 minutes (T1), 1 hour (T2), 2 hours (T3), 4 (T4) and 6 hours (T5) after surgery. In addition, haemoglobin (Hb) values and adverse events were observed. Inferential statistical tests were used to analyze differences between the two groups. The level of pain in the Metamizole group was lower than Ketorolac group at T1 and T2 (2.71 versus 2.18, p=0.001; and 2.51 versus 2.11, p=0.000; respectively). The AUC values between the two groups showed a statistical difference (p=0.02). The Hb values pre- and post-TURP were significantly different in Metamizole as well as Ketorolac groups (all p=0.001), but there was no difference between groups. This finding indicates that Metamizole injection can be considered as an alternative  for post-TURP analgesic with better availability and lower cost
Co-Authors Adji Prayitno Setiadi Anak Agung Gede Sugianthara Dwi Octamy Sari Erfin Midhiawati Faiz Farikhah Fauna Herawati Ferdias Kurnia Bahari Firmansah, Moh. Linda Wahyuni Wongkar Riza Mazidu Sholihin Sandra Annisa Wibowo, Yosi Irawati